Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLia PalombaBHBrian T. HillMKManali Kamdar

Discussion

Loading...

Member takes

Overview

Liso-cel shows clinically meaningful improvements in quality of life and functioning in R/R MZL patients, supporting its potential standard of care role.

Key Points

  • Most patients with 3L+ R/R MZL showed clinically meaningful improvements in patient-reported outcomes after liso-cel therapy.
  • Quality of life improvements were noted across multiple EORTC QLQ-C30 domains, with 4 exceeding meaningful thresholds.
  • Assessment results were based on linear mixed-effects models, with high completion rates noted through Month 18.
  • Findings emphasize liso-cel's role in enhancing patient experience post-treatment for 3L+ R/R MZL.

Cite This Study

Palomba et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c3https://doi.org/10.1182/blood-2025-709
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL2025 · 2 citations
  2. 2Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM2025 · 1 citations
  3. 3Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations
  4. 4Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025
  5. 5Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study2026 · 1 citations